Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
Open Access
- 1 July 2017
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 15 (7), 1448-1452
- https://doi.org/10.1111/jth.13716
Abstract
No abstract availableFunding Information
- Ablynx
This publication has 19 references indexed in Scilit:
- Prognostic risk‐stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012Transfusion, 2016
- Von Willebrand Factor — A New Target for TTP Treatment?The New England Journal of Medicine, 2016
- Caplacizumab for Acquired Thrombotic Thrombocytopenic PurpuraThe New England Journal of Medicine, 2016
- Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortalityBlood, 2015
- Cardiac troponin‐I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference CenterJournal of Thrombosis and Haemostasis, 2014
- Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathiesBritish Journal of Haematology, 2012
- Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experienceHaematologica, 2012
- How I treat patients with thrombotic thrombocytopenic purpura: 2010Blood, 2010
- Survival and relapse in patients with thrombotic thrombocytopenic purpuraBlood, 2010
- Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraBlood, 2008